1077 related articles for article (PubMed ID: 16754727)
1. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
[TBL] [Abstract][Full Text] [Related]
3. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
Vogel VG
Expert Rev Anticancer Ther; 2009 Jan; 9(1):51-60. PubMed ID: 19105706
[TBL] [Abstract][Full Text] [Related]
4. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
[TBL] [Abstract][Full Text] [Related]
5. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
Dunn BK; Ford LG
Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
[TBL] [Abstract][Full Text] [Related]
6. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
[TBL] [Abstract][Full Text] [Related]
7. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
[TBL] [Abstract][Full Text] [Related]
8. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
10. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
Vogel VG
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
[TBL] [Abstract][Full Text] [Related]
12. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.
Nelson HD; Fu R; Griffin JC; Nygren P; Smith ME; Humphrey L
Ann Intern Med; 2009 Nov; 151(10):703-15, W-226-35. PubMed ID: 19920271
[TBL] [Abstract][Full Text] [Related]
13. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Barrett-Connor E; Mosca L; Collins P; Geiger MJ; Grady D; Kornitzer M; McNabb MA; Wenger NK;
N Engl J Med; 2006 Jul; 355(2):125-37. PubMed ID: 16837676
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention for high-risk women: tamoxifen and beyond.
Fabian CJ; Kimler BF
Breast J; 2001; 7(5):311-20. PubMed ID: 11906441
[TBL] [Abstract][Full Text] [Related]
15. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
16. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
[TBL] [Abstract][Full Text] [Related]
17. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
18. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
19. The use of tamoxifen and raloxifene for the prevention of breast cancer.
Wickerham DL; Costantino JP; Vogel VG; Cronin WM; Cecchini RS; Ford LG; Wolmark N
Recent Results Cancer Res; 2009; 181():113-9. PubMed ID: 19213563
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
